Peptides in Diabetes Research
Peptide-based research has revolutionized the understanding of diabetes and metabolic disease. GLP-1 agonists, dual agonists, and related peptides are at the forefront of metabolic research.
GLP-1 Agonists in Diabetes Research
Semaglutide is the gold standard single GLP-1 agonist, with demonstrated effects on: glucose-dependent insulin secretion (reduces hypoglycemia risk), beta cell preservation research, HbA1c reduction in clinical trials, and post-meal glucose excursion control.
Dual and Triple Agonists
Tirzepatide (GIP/GLP-1) shows superior glucose control in research, potentially through additive insulinotropic effects from both incretin pathways. Retatrutide (GLP-1/GIP/glucagon) adds hepatic glucose regulation through glucagon receptor activation, creating a triple approach to metabolic homeostasis.
Beyond Glucose Control
Modern diabetes peptide research extends beyond blood sugar: cardiovascular risk reduction, weight management (critical in type 2 diabetes), hepatic steatosis (fatty liver) improvement, renal protective effects, and potential disease modification (beta cell preservation).
Amylin Analogs
Amylin is a peptide co-secreted with insulin that slows gastric emptying and suppresses glucagon. Cagrilintide (long-acting amylin analog) is being researched in combination with semaglutide for enhanced metabolic effects.
MOTS-C and Metabolic Research
MOTS-C activates AMPK, the same pathway targeted by metformin, making it valuable for studying exercise-mimetic effects on glucose metabolism and insulin sensitivity.
Related Articles: How GLP-1 Agonists Work | The Incretin Effect | GLP-1 Overview
For research use only. Shop metabolic research peptides at Proxiva Labs with verified COAs.
All products are sold strictly for research purposes only. Not for human consumption.